CollPlant Biotechnologies (CLGN) Operating Expenses (2017 - 2026)
CollPlant Biotechnologies' (CLGN) quarterly Operating Expenses came in at $2.9 million in Q1 2026, down 18.29% YoY from $3.5 million in Q1 2025, and down 4.84% on a QoQ basis from $3.0 million in Q4 2025.
CollPlant Biotechnologies (CLGN) Operating Expenses (2017 - 2026) Analysis & Trends
CollPlant Biotechnologies (CLGN) has 10 years of Operating Expenses data on file, last reported at $2.9 million in Q1 2026.
- Quarterly Operating Expenses fell 18.29% year-over-year to $2.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $12.4 million (down 21.54% YoY) and the FY2025 annual result came in at $13.0 million, down 19.34% from the prior year.
- Operating Expenses fell to $2.9 million in Q1 2026, from $3.0 million in the prior quarter.
- In the past five years, Operating Expenses ranged from a high of $4.7 million in Q4 2022 to a low of $92000.0 in Q1 2022.
- A 5-year average of $3.6 million and a median of $3.9 million in 2024 frame the typical range for Operating Expenses.
- Annual changes were most pronounced in 2022 — Operating Expenses tumbled 97.44% — and 2023, when it surged 3842.39%.
- Tracing CLGN's Operating Expenses over 5 years: stood at $4.7 million in 2022, then fell by 1.67% to $4.6 million in 2023, then declined by 15.85% to $3.9 million in 2024, then dropped by 21.93% to $3.0 million in 2025, then dropped by 4.84% to $2.9 million in 2026.
- The last three Operating Expenses figures came in at $2.9 million (Q1 2026), $3.0 million (Q4 2025), and $3.3 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 2.89 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 960.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 1.21 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1.06 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 427.03 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 541.02 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -784.57 Mn |
| 10 | CollPlant Biotechnologies | 4.13 Mn | 4.13 Mn | -243,000.00 | 2.87 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 30, 2026 | 2.87 Mn |
| Dec 31, 2025 | 3.02 Mn |
| Sep 30, 2025 | 3.32 Mn |
| Jun 30, 2025 | 3.17 Mn |
| Mar 30, 2025 | 3.52 Mn |
| Dec 31, 2024 | 3.87 Mn |
| Sep 30, 2024 | 4.27 Mn |
| Jun 30, 2024 | 4.12 Mn |
| Mar 31, 2024 | 3.88 Mn |
| Dec 31, 2023 | 4.59 Mn |
| Sep 30, 2023 | 4.37 Mn |
| Jun 30, 2023 | 3.89 Mn |
| Mar 31, 2023 | 3.63 Mn |
| Dec 31, 2022 | 4.67 Mn |
| Sep 30, 2022 | 4.31 Mn |
| Jun 30, 2022 | 4.21 Mn |
| Mar 31, 2022 | 92,000.00 |
| Dec 31, 2021 | 3.57 Mn |
| Sep 30, 2021 | 3.09 Mn |
| Jun 30, 2021 | 3.33 Mn |